ArticlePharmacological reports : PR2024

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot-β-cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers.

Joanna Pilch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.